Nachrichten zur Axsome Therapeutics Aktie

Axsome Therapeutics SWOT analysis: strong growth, pipeline potential lift stock By Investing.com

Axsome Therapeutics SWOT analysis: strong growth, pipeline potential lift stock…

Axsome Therapeutics: 80 % Umsatzwachstum durch neue Therapien des zentralen Nervensystems

Biopharmazeutische Unternehmen konzentrieren sich meist auf die Behandlung schwerwiegender und oft unzureichend behandelter Erkrankungen. Entsprechend groß ist der Bedarf an…

Axsome Therapeutics Aktie: Positive Überraschung gelungen!

Die Axsome Therapeutics Aktie verzeichnet zum Ende des Jahres 2024 eine bemerkenswerte Marktpräsenz mit einer Marktkapitalisierung von 4,5 Milliarden Euro.…

Is It Too Late to Buy Viking Therapeutics Stock?

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a…

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

AXSM earnings call for the period ending September 30, 2024.…

Axsome Therapeutics, Inc. 2024 Q3 - Results - Earnings Call Presentation

…

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics Aktie: FDA akzeptiert erneuten Zulassungsantrag

Die Axsome Therapeutics Aktie zeigt sich stabil bei 80,25 EUR, während das Unternehmen einen wichtigen regulatorischen Meilenstein erreicht hat. Die…

Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz

…

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript

AXSM earnings call for the period ending June 30, 2024.…

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

…

Axsome Therapeutics Q2 2024 Earnings Preview

…

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…

Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript

AXSM earnings call for the period ending March 31, 2024.…

Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript

…

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced cataplexy attacks compared to placebo (p=0.018, primary endpoint)…

Earnings call: Axsome Therapeutics reports solid growth in 2023 By Investing.com

Earnings call: Axsome Therapeutics reports solid growth in 2023…

Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript

…

Axsome Therapeutics (AXSM) Q4 2023 Earnings Call Transcript

AXSM earnings call for the period ending December 31, 2023.…

Axsome Therapeutics a new outperform at RBC on underappreciated pipeline

…

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally…

Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

Investors can contact the law firm at no cost to learn more about recovering their losses…

Global Sleep Apnea Oral Appliances Market Size Worth USD 1.55 Billion By 2032 | CAGR of 13.2%

The Global Sleep Apnea Oral Appliances Market Size was valued at USD 0.45 Billion in 2022 and the Worldwide Sleep…

AXSM DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action – AXSM

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)

…

Axsome Therapeutics (AXSM) Q3 2023 Earnings Call Transcript

AXSM earnings call for the period ending September 30, 2023.…

Axsome Therapeutics, Inc. (AXSM) Q3 2023 Earnings Call Transcript

…

Axsome Therapeutics Q3 2023 Earnings Preview

…

Axsome Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and…

dpa-AFX ProFeed